Pharma Pulse: FDA Warns ImmunityBio Over Misleading Claims and MedImpact’s New GLP-1 Programs

In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and MedImpact launches new solutions to address the skyrocketing employer costs of GLP-1 weight management therapies.